Ignite Creation Date:
2024-05-06 @ 7:43 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06118398
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-07
First Post:
2023-11-01
Brief Title:
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
Sponsor:
Feng Jinzhou
Organization:
First Affiliated Hospital of Chongqing Medical University
Study Overview
Official Title:
Effectiveness and Safety of Efgartigimod in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric Controlled Retrospective Real-Word Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders NMOSD patients
Detailed Description:
This is a multicentre controlled retrospective real-world study which aims to compare the safety and effectiveness of Intravenous methylprednisolone IVMP with Efgartigimod injection add-on treatment with IVMP treatment in acute NMOSD patients Twenty-four patients from 6 centres in China will be enrolled
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None